Skip to main content
OpenTrials
Completed

NCT Number: NCT01735305

Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease

Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years old who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were physician discretion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The first affiliated hospital of Bengbu Medical College, Bengbu, Anhui, China

Loading trial locations.

About this study

Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were at physician discretion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of coronary heart disease
  • Age >= 18 years old
  • receiving any antiplatelet agents
  • Informed written consent signed

Exclusion criteria

  • With severe disease and life expectancy for 6 months or less
  • Difficult to attain follow-up situations judged by researchers (travel, speech or mental disorder, etc.)
  • Taking part in an interventional clinical research

Treatment and study plan

Primary outcomes

  1. Major adverse cardiac and cerebral events

    Time frame: 12month

    a composite of all cause death, myocardial infarction, stroke or any revascularization or stroke

Secondary outcomes

  1. all cause death

    Time frame: 12month

  2. Stent thrombosis

    Time frame: 12 month

    by BARC definition

  3. rehospitalization

    Time frame: 12 month

    any rehospitalization for cardiac or noncardiac reasons

  4. any bleeding events

    Time frame: 12 month

    by BARC definition

  5. recurrent angina

    Time frame: 12 month

  6. myocardial infarction

    Time frame: 12 months

  7. stroke

    Time frame: 12 months

  8. any revascularization

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Shenyang Northern Hospital

Other

Collaborators

  • Guangdong Provincial People's Hospital

Registry information

Acronym: OPT-CAD

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
Nov 28, 2012
Registry last updated
Dec 11, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.